• Bringing diversity

    into industrial processes

About IMMT

Using information buried in nature to obtain novel bioactive compounds as enzymes

Institute of Metagenomics and Microbial Technologies (IMMT) is committed to make new compounds from bacterial communities in nature, like enzymes. The focus of IMMT is to develop customised solutions for our clients specific problems. The solutions are based on novel bioactive natural compounds produced by microbes for successful medical and industrial applications.

IMMT is build on its founders wide experiences in analyzing the functioning of microbial communities in the last 15 years. By working on over 40 research and industrial projects, they have developed proprietary technologies for the extraction and processing of information of the DNA/RNA from bacteria present in native environments.

We look forward to bring diversity into your industrial and manufacturing processes and make your products more efficient. Please contact us by E: immt@immt.eu or T: +386 (0)41 966 665.

Advisory board

Cooperating for 5 years

Ales Lapanje, PhD

Dr Ales Lapanje
LinkedIn - Dr Ales Lapanje
Dr Ales Lapanje is a co-founder of Institute of Metagenomics and Microbial Technologies (IMMT) and a researcher at Jozef Stefan Institute (IJS), Slovenia, which is ranked among the top 10 research institutes in Europe. Dr Ales Lapanje received his PhD in molecular microbial ecology. He has 15 years of experience in environmental molecular microbiology, focusing on the functioning of microbial communities in various environments. He published 50 scientific articles, carried over 40 academic and industrial projects and holds 4 patents and 5 patent applications.

Dr Ales Lapanje has developed several technologies and commercial platforms which were commercialized by means of licensing as well as 5 spinoff companies. For his contributions in microbiology research he received awards such as FEMS-Federation of European Microbiologists award for research, World Federation of Scientists award, CCIS Innovation Award which is handed out by the Chamber of Commerce and Industry of Slovenia, and L'Oreal-UNESCO FWIS award for a woman scientist of the year where he was a supervisor.

Tomaz Rijavec, PhD

Dr Tomaz Rijavec
LinkedIn - Dr Tomaz Rijavec
Dr Tomaz Rijavec is a co-founder of IMMT and a researcher at the Department of Environmental Sciences at Jozef Stefan Institute. He holds a PhD in molecular biology. He has more than 10 years of research experience in the field of molecular biology and biochemistry. His work has been focused on studying the functioning of microbial communities, host-microbe interactions and characteristics of different micro-environments.

Dr Tomaz Rijavec has been involved in several national and international applicative projects, aiming to translate basic science into applicative solutions. He has supervised the setting up of several analytics pipelines and laboratories for molecular biology. He is an expert at method development and validation.

Jan Zrimec, PhD

LinkedIn - Dr Jan Zrimec
Dr Jan Zrimec is a postdoctoral researcher at the Faculty of Health Sciences, University of Primorska, Slovenia. He has a PhD in bioinformatics and he was recently awarded the National ARRS postdoctoral research fellowship.

Dr Jan Zrimec has over 6 years of experience in computational biology and bioinformatics of DNA signatures. The aim of his work is to develop bioinformatic algorithms based on computation and analysis of DNA structure and horizontal gene transfer to:
- analyse and reduce the emergence of antibiotic resistance in bacterial communities,
- improve the efficiency and accuracy of discovery of new bioactive compounds useful in industrial and medical applications.


The window of opportunity is now

Driven by the belief that our team at the Institute of Metagenomics and Microbial Technologies (IMMT) can make a great contribution to global health and wellbeing, we put all our knowledge, effort and time into obtaining new compounds from bacterial communities in nature, like enzymes.

Our solution enables over 6 orders of magnitude higher probability to get something new and bioactive. It uses application directed approach to obtain new molecules from information coded in the DNA/RNA molecules from bacteria present in native environments. This approach allows the highest probability to obtain new bioactive compounds needed for successful medical and industrial applications.

Our founders can make this possible due to their strong fundamental knowledge and experience in the functioning of microbial communities which was gained in 15 years of scientific and applicative research.

At the moment we are looking for strategic partners and investors to help us realize our vision of creating a novel platform for new, natural bioactive compounds.


July 2016

New ways of developing bioactive compounds

The Institute of Metagenomics and Microbial Technologies (IMMT) receives funding to develop new bioactive compounds.

The Slovene Enterprise Fund has recently granted 42.000,00 EUR to IMMT to commercialize its platform for development of new bioactive compounds. The platform can be used in medicine, nutrition and environmental technologies. The investment was co-financed by the Republic of Slovenia and the European Union under the European Regional Development Fund.

Name of the operation: Commercialization of the technology platform for the development of new bioactive compounds for the use in biotechnology applications.

Link to the website of the European Cohesion Policy in Slovenia: www.eu-skladi.si

IMMT Contact


Institute of Metagenomics and Microbial Technologies Ltd. (IMMT)
Clevelandska 19
SI - 1000 Ljubljana, Europe
E-mail: immt@immt.eu
Web: www.immt.eu

Contact person

Blaz Petric, CEO
Tel.: +386 (0)41 966 665
E-mail: blaz.petric@immt.eu